Drug Profile
CN 764
Latest Information Update: 28 May 2007
Price :
$50
*
At a glance
- Originator Calydon
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 04 Aug 1999 Preclinical development for Prostate cancer in USA (Unknown route)